Clinical trial
Safety & Immunogenicity Study of Meningococcal Vaccine GSK134612 Given With…
NCT00474266 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00474266 |
|---|---|
| Title | Safety & Immunogenicity Study of Meningococcal Vaccine GSK134612 Given With Priorix-Tetra™ to 12-23 Month-Old Children |
| Official title | Immunogenicity & Safety Study of GSK Biologicals' Meningococcal Vaccine GSK134612 When Co-Administered With GSK Biologicals' MMRV Vaccine (Priorix-Tetra™) in Healthy 12 to 23-Month-Old Children |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Infections, Meningococcal |
| Intervention type | Biological |
| Interventions | Meningococcal vaccine GSK134612 (Nimenrix), Priorix-Tetra, Meningitec |
| Enrollment | 1,000 |
| Start date | Jun 5, 2007 |
| Primary completion | Feb 26, 2008 |
| Completion | Mar 26, 2008 |
| First posted | May 16, 2007 |
| Last update posted | Nov 18, 2019 |
| Countries | Finland |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: